Pharmaceutical News

RSS

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

...

5 Sep 2013

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

...

5 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

Natural products: The source of nearly half of modern drugs

New technology for discovering antibiotics, anti-cancer drugs and other medicines inside soil microbes and other natural sources is reviving a treasure hunt that already has given humanity more than 50 percent of today's prescription drugs. This new era in "bioprospecting" is the topic of the cover story in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society.

5 Sep 2013

Research into 'personalised' medicine is being led by Greenwich team

Research into 'personalised' medicine is being led by a University of Greenwich team. Currently, many medicines which are prescribed to patients either do not work properly or have some significant side effects. The aim of personalised medicine, sometimes called 'precision' medicine, is to ensure that the most appropriate medicine is given to each patient and that the medicine is both effective and safe.

5 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

New influenza vaccine delivered via microneedle avoids pain and side effects

Scientists have developed an influenza vaccine delivered via microneedle patch that provided 100 percent protection against a lethal influenza virus in mice more than one year after vaccination. They report their findings in the September 2013 issue of the journal Clinical and Vaccine Immunology.

5 Sep 2013

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

The findings were presented at the ESC Congress today by Ms Stina Jakobsson from Sweden. They reveal that reperfusion therapy and secondary prevention drugs produced the decline and brought stroke risk after AMI closer to that of non-diabetics.

5 Sep 2013

Scientists develop new form of aspirin to cope with resistance

Scientists are reporting development of a new form of aspirin - taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke - that could extend aspirin's benefits to people who may not respond to the drug. Their advance toward coping with "aspirin resistance" appears in the journal ACS Nano.

5 Sep 2013

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Resveratrol, a polyphenolic compound, is synthesized in several plants and possesses beneficial biological effects, which include anti-oxidant, anti-inflammatory and anti-carcinogenic properties.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

People with CVD more likely to take preventive medicines when combined in one pill

People are much more likely to take preventive medicines if they're combined in one pill, an international study has found. The findings are published today in the Journal of the American Medical Association.

5 Sep 2013

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi US and POZEN Inc. announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet ("PA"), PA8140 and PA32540.

5 Sep 2013

Myriad, Astrazeneca Expand Collaboration On Olaparib

...

4 Sep 2013

Dakota Laboratories banned from manufacturing and distributing drugs

Dakota Laboratories LLC and its president, Charles L. Voellinger, Sr., are prohibited from manufacturing and distributing drugs until they correct their ongoing violations of the drug manufacturing laws.

4 Sep 2013

New Ebook lists the top 5 influencers in pharma compliance

...

4 Sep 2013

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.

4 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Pharmaceutical News

Karo Wins First Milestone For Autoimmune Disease Deal With Pfizer

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

Natural products: The source of nearly half of modern drugs

Research into 'personalised' medicine is being led by Greenwich team

Study finds similar antibody levels among 4 PCV13 immunization schedules

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

New influenza vaccine delivered via microneedle avoids pain and side effects

Secondary prevention drugs produce decline in stroke risk after AMI in diabetic patients

Scientists develop new form of aspirin to cope with resistance

Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

People with CVD more likely to take preventive medicines when combined in one pill

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Myriad, Astrazeneca Expand Collaboration On Olaparib

Dakota Laboratories banned from manufacturing and distributing drugs

New Ebook lists the top 5 influencers in pharma compliance

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Study: Fixed-dose combination medication helps CVD patients

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News